The PARP inhibitor olaparib has just been approved for maintenance treatment in advanced ovarian cancers with germline BRCA mutation and several phase III clinical trials are in progress for the treatment of breast and ovarian cancers with BRCA mutations [20]. The gene discussed is PARP1; the disease is ovarian cancer.